Results(4675)
The Swedish Multiple Sclerosis Registry
Disease registry
Sweden
First published:
09/06/2026
Data source
Human
Record completeness: 90%
Oslo University Hospital Clinical Data Warehouse
Hospital discharge records
Hospital inpatient records
Hospital outpatient visit records
Other
Norway
First published:
09/06/2026
Data source
Human
Record completeness: 91%
The European HBV Registry - A joint initiative of TherVacB and DZIF
Disease registry
Germany
Italy
Spain
First published:
09/06/2026
Data source
Human
Record completeness: 87%
Pregnancy Exposures and Outcomes in Women with Inflammatory Bowel Disease Treated with Risankizumab: A Cohort Study Utilizing Large Electronic Healthcare Databases with Mother-Baby Linkage in the United States
United States
EU PAS number:
EUPAS1000000283
First published:
09/06/2026
Study
Ongoing
DARWIN EU® - Characterising the use of JAK inhibitors in Europe: a Drug Utilisation Study Update
Croatia
Denmark
Finland
Germany
Spain
Sweden
EU PAS number:
EUPAS1000000998
First published:
09/06/2026
Study
Ongoing
DARWIN EU® - Characteristics of individuals with acute graft vs. host disease with intestinal involvement
France
Germany
Spain
EU PAS number:
EUPAS1000000878
First published:
09/06/2026
Study
Ongoing
The European HBV Registry: A joint initiative of TherVacB and DZIF (HBV Registry)
Germany
Italy
Spain
United Kingdom
EU PAS number:
EUPAS42767
First published:
09/06/2026
Study
Ongoing
TARGET-EU: Feasibility assessment based on the Data Quality Framework for EU medicines regulation.
Belgium
Denmark
Finland
Greece
Italy
Netherlands
Spain
United Kingdom
EU PAS number:
EUPAS1000000791
First published:
08/06/2026
Study
Finalised
The Valencia Health System Integrated Database
Hospital outpatient visit records
Other
Primary care medical records
Registration with healthcare system
Spain
First published:
08/06/2026
Data source
Human
Record completeness: 97%
Ustekinumab and Risk of Small for Gestational Age in Inflammatory Bowel Disease Pregnancies: Data from the DUMBO Registry
Spain
EU PAS number:
EUPAS1000001012
First published:
05/06/2026
Study
Finalised
Pan European Prospective Observational Study of Fremanezumab effectiveness in patients with chronic or episodic migraine in the Real-World: PEARL study
Czechia
Denmark
Finland
Greece
Italy
Norway
Portugal
Spain
Sweden
Switzerland
United Kingdom
EU PAS number:
EUPAS35111
First published:
05/06/2026
Study
Finalised
Observational Cohort Study Evaluating Real-World ABRYSVO Vaccine Effectiveness and Impact Against Medically-Attended RSV-related and All-Cause Outcomes Among Infants Born to Individuals Vaccinated During Pregnancy
United States
EU PAS number:
EUPAS1000000295
First published:
05/06/2026
Study
Ongoing
OBSERVATIONAL SAFETY AND EFFECTIVENESS STUDY OF PATIENTS WITH POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS TREATED WITH TOCILIZUMAB
Germany
United States
EU PAS number:
EUPAS10547
First published:
05/06/2026
Study
Finalised
Prospective observational study to assess the long term safety profile of venetoclax in a Swedish cohort of Chronic Lymphocytic Leukaemia (CLL) patients
Sweden
EU PAS number:
EUPAS19010
First published:
05/06/2026
Study
Ongoing
Demyelinating Risk with TNF Inhibitors versus Other Targeted DMARDs in Rheumatoid Arthritis: A French Nationwide Claims Study (DEMY-TNF)
France
EU PAS number:
EUPAS1000001021
First published:
05/06/2026
Study
Ongoing
A prospective non-interventional post-authorization safety study (PASS) of lenalidomide in previously untreated adult multiple myeloma patients who are not eligible for transplant (“transplant noneligible” [TNE]) (“Revlimid® TNE NDMM PASS”) (CC-5013-MM-034)
Austria
Belgium
Denmark
France
Germany
Ireland
Italy
Netherlands
Norway
Spain
Sweden
United Kingdom
EU PAS number:
EUPAS10153
First published:
04/06/2026
Study
Ongoing
Post-marketing Study Assessing the Serious Cardiovascular Events Among Osteoporotic Patients Initiating Romosozumab in Japan Using the Medical Information Database Network (MID-NET) (20190206)
Japan
EU PAS number:
EUPAS1000000308
First published:
04/06/2026
Study
Ongoing
Long-term cardiovascular safety and real-world use of eptinezumab - An observational, historical cohort study of patients initiating eptinezumab in routine clinical practice
Denmark
Germany
Italy
United States
EU PAS number:
EUPAS1000000882
First published:
03/06/2026
Study
Planned
OXON Epidemiology
Spain
United Kingdom
First published:
03/06/2026
Institution
Laboratory/Research/Testing facility
Non-Pharmaceutical company
ENCePP partner
A Post-Authorisation Safety Study (PASS) of ABRYSVO (Respiratory Syncytial Virus Stabilised Prefusion Subunit Vaccine) in Pregnant Women and their Offspring in a Real World Setting in Europe and UK (C3671026)
Denmark
France
Netherlands
Norway
Spain
United Kingdom
EU PAS number:
EUPAS1000000399
First published:
03/06/2026
Study
Ongoing
Evaluation of the effectiveness of Penthrox® (methoxyflurane) educational tools adopted as additional risk minimisation measures: Healthcare professional and Patient Survey (Penthrox-Survey)
United Kingdom
EU PAS number:
EUPAS13034
First published:
03/06/2026
Study
Finalised
Myozyme (alglucosidase alfa) Safety Information Packet effectiveness evaluation: a health care professional survey
France
Germany
Italy
Poland
Spain
United Kingdom
EU PAS number:
EUPAS10301
First published:
03/06/2026
Study
Finalised
Evaluation of the effectiveness of the belatacept (Nulojix®) Patient Alert Card in patients following renal transplantation in European Economic Area countries.
Austria
France
Germany
Sweden
EU PAS number:
EUPAS10046
First published:
03/06/2026
Study
Finalised
Evaluation of the effectiveness of the abatacept (ORENCIA®) intravenous and subcutaneous formulation Patient Alert Cards in patients with rheumatoid arthritis in a sample of European Economic Area countries
France
Germany
Spain
Sweden
United Kingdom
EU PAS number:
EUPAS10122
First published:
03/06/2026
Study
Finalised
Post Authorisation Safety Study (PASS) to Evaluate the Risks of Hepatotoxicity and Nephrotoxicity from Administration of Methoxyflurane (Penthrox®) for Pain Relief in Hospital Accident & Emergency Departments in the United Kingdom (Penthrox-PASS)
United Kingdom
EU PAS number:
EUPAS13040
First published:
03/06/2026
Study
Finalised
Non-interventional study with Binosto 70 mg effervescent tablets once weekly investigating gastro-intestinal events and medication errors (Gastro-PASS)
Italy
Spain
EU PAS number:
EUPAS10888
First published:
03/06/2026
Study
Finalised
Characterising the safety profile of lurasidone in clinical practice: A drug utilisation and safety study using a United Kingdom primary care database
United Kingdom
EU PAS number:
EUPAS18536
First published:
03/06/2026
Study
Planned
A prospective study to evaluate the safety, effectiveness and impact of the RTS, S/AS01E vaccine in young children in sub-Saharan Africa (EPI-MALARIA-003 VS AME) (115056)
Ghana
Kenya
Malawi
EU PAS number:
EUPAS28541
First published:
03/06/2026
Study
Finalised
Vedolizumab-4081: Infection Outcomes among Advanced Therapy-naive Older Adult US Patients With UC/CD Initiating ENTYVIO, TNF-alpha Inhibitors, or Ustekinumab: A Retrospective Observational Matched-Cohort Study Using Medicare Claims Data, 2016-2025
United States
EU PAS number:
EUPAS1000000767
First published:
03/06/2026
Study
Ongoing
Impact of biologics on inhaled corticosteroids reduction (MOON LIGHT)
Argentina
Belgium
Brazil
Bulgaria
Canada
Colombia
Denmark
Estonia
France
Greece
India
Ireland
Italy
Japan
Korea, Republic of
Kuwait
Mexico
Norway
Poland
Portugal
Saudi Arabia
Singapore
Spain
Taiwan
United Arab Emirates
United Kingdom
United States
EU PAS number:
EUPAS1000000855
First published:
03/06/2026
Study
Ongoing
Sustainability of response to biologics in severe asthma and predictors of late failure among patients in an international registry (SHINE)
Argentina
Belgium
Brazil
Bulgaria
Canada
Colombia
Denmark
Estonia
Greece
Ireland
Italy
Japan
Korea, Republic of
Kuwait
Mexico
Norway
Poland
Portugal
Saudi Arabia
Singapore
Spain
Taiwan
United Arab Emirates
United Kingdom
United States
EU PAS number:
EUPAS1000000788
First published:
03/06/2026
Study
Ongoing
Centre for Pharmacoepidemiology, Karolinska Institutet (CPE-KI)
Sweden
First published:
02/06/2026
Institution
Educational Institution
Laboratory/Research/Testing facility
Not-for-profit
ENCePP partner
Yale University Medical School Department of Neurosurgery (Yale)
United States
First published:
02/06/2026
Institution
Hospital/Clinic/Other health care facility
Maternal and Postnatal Outcomes: A worldwide decentralized observational registry to evaluate the safety in women with Fabry disease and their infants after exposure to Elfabrio (pegunigalsidase alfa-iwxj/pegunigalsidase alfa) during pregnancy and/or lactation
Germany
Italy
Spain
United Kingdom
United States
EU PAS number:
EUPAS1000000957
First published:
02/06/2026
Study
Ongoing
DARWIN EU® - Chondrosarcoma: patient demographics, treatments, and survival in the period 2010-2023
Finland
France
Netherlands
Spain
United Kingdom
EU PAS number:
EUPAS1000000162
First published:
02/06/2026
Study
Finalised
A Non-Interventional Post-Approval Safety Study of Pfizer-BioNTech COVID-19 Vaccine in the United States
United States
EU PAS number:
EUPAS43468
First published:
02/06/2026
Study
Finalised
DARWIN EU® - Assessing the feasibility of conducting a causal study on the potential association between beta-blockers and breast cancer
Denmark
Norway
Spain
Sweden
United Kingdom
EU PAS number:
EUPAS1000001013
First published:
02/06/2026
Study
Ongoing
International Registries for Rare Conditions Affecting Sex Development & Maturation (SDMregistries; formerly known as I-DSD/I-CAH/I-TS /I-HH)
Disease registry
Angola
Argentina
Armenia
Australia
Austria
Bangladesh
Belgium
Bosnia and Herzegovina
Brazil
Bulgaria
Cameroon
Canada
China
Croatia
Cyprus
Czechia
Denmark
Egypt
France
Georgia
Germany
Greece
Hong Kong
Hungary
India
Indonesia
Ireland
Israel
Italy
Japan
Jordan
Kenya
Kuwait
Lithuania
Malaysia
Mexico
Montenegro
Morocco
Netherlands
Nigeria
Norway
Oman
Pakistan
Philippines
Poland
Portugal
Romania
Russian Federation
Serbia
Singapore
Slovakia
South Africa
Spain
Sri Lanka
Sudan
Sweden
Switzerland
Taiwan
Tanzania, United Republic of
Thailand
Türkiye
Uganda
Ukraine
United Arab Emirates
United Kingdom
United States
Uzbekistan
Viet Nam
First published:
01/06/2026
Data source
Human
Record completeness: 96%
Real World Outcomes of Patients Treated with Vericiguat in German Routine Care (ROVER)
Germany
EU PAS number:
EUPAS1000000221
First published:
01/06/2026
Study
Ongoing
Compare data sources
Compare data sources